Medicus Pharma (MDCX) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scilex (SCLX) has outperformed Medicus Pharma (MDCX) over the past year, losing 73.0% versus a loss of 95.9%. Scilex is the larger company by market cap ($20.8 million vs $7.3 million), about 2.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDCX | SCLX |
|---|---|---|
| Share price | $0.1019 | $2.96 |
| Market cap | $7.31M | $20.82M |
| 1-day change | -36.39% | -15.19% |
| YTD return | -93.34% | -61.03% |
| 1-year return | -95.86% | -72.96% |
| 5-year return | — | -98.65% |
| Forward P/E | — | 4.05 |
| EPS (TTM) | $-2.38 | $-42.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.78 | $16.81 |
| 52-week low | $0.0941 | $2.62 |
| Distance from 52-week high | -96.33% | -82.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +4316.09% | — |
| Average volume | 4.43M | 54.58K |
| Shares outstanding | 71.71M | 7.03M |
| Employees | 16 | 34 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Scilex is about 2.8 times larger than Medicus Pharma by market value ($20.82M vs $7.31M).
- SCLX has outperformed MDCX by 22.9 percentage points over the past year.
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Healthcare · Drug Manufacturers - General · 16 employees
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Healthcare · Drug Manufacturers - General · 34 employees
MDCX vs SCLX FAQ
Which is bigger, Medicus Pharma or Scilex?
Scilex (SCLX) is larger, with a market capitalization of $20.82M compared with $7.31M for Medicus Pharma (MDCX).
Which stock has performed better over the past year, MDCX or SCLX?
SCLX returned -72.96% over the past 12 months, compared with -95.86% for MDCX (price return, excluding dividends). Past performance does not predict future results.
Are Medicus Pharma and Scilex in the same industry?
Yes. Both are classified in the Drug Manufacturers - General industry within the Healthcare sector.